Stock profile

CLASSYS Inc.(214150.KQ)

Country: South KoreaSector: HealthcareIndustry: Medical - DevicesExchange: KOE
P/E TTM
19.2
History
P/E NTM
18.1
Market cap
3.16T
Currency KRW
KvantraRanki51
Value37
Quality75
Momentum38
Current price
39,700.00-9.36%
Benchmarks

No price history available.

Key financial summary

Financials in KRW
202020212022202320242025TTM2026E
Total revenueKRWm76,461100,597141,803180,123242,939336,800N/AN/A
Operating profitKRWmLockedLockedLockedLockedLockedLockedLockedLocked
Net profitKRWm38,16543,80575,37974,22597,875131,900N/AN/A
EPS reportedKRWLockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per shareKRWLockedLockedLockedLockedLockedLockedLockedLocked
Capex per shareKRWLockedLockedLockedLockedLockedLockedLockedLocked
FCF per shareKRWLockedLockedLockedLockedLockedLockedLockedLocked
Free cash flowKRWmLockedLockedLockedLockedLockedLockedLockedLocked
Net debtKRWmLockedLockedLockedLockedLockedLockedLockedLocked
Book value equityKRWmLockedLockedLockedLockedLockedLockedLockedLocked
Book value per shareKRWLockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)KRWLockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in KRW
202020212022202320242025TTM2026E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLocked

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Company overview

CLASSYS Inc. is a global supplier of sophisticated medical aesthetic devices. Its diverse product range features SCIZER, a non-invasive solution for subcutaneous fat reduction; ULTRAFORMER MPT, which employs focused ultrasound stimulation for skin tissue coagulation to achieve eyebrow lifts; and ULTRAFORMER III, a high-intensity focused ultrasound (HIFU) surgical device designed for tissue coagulation, aiding in eyelid lifting, skin tightening, and improving subcutaneous tissue elasticity across the face (cheeks), abdomen, and thighs, while also diminishing crow's feet, laugh lines, and neck wrinkles. Additional offerings include INTRASURE, a versatile multi-platform solution for aesthetics and healthcare; FORSHAPE, an RF treatment system engineered to boost metabolism, enhance blood circulation, and facilitate tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used for skin tissue coagulation as a general electrosurgical instrument. The company's portfolio further encompasses CLATUU Alpha, a medical device that progressively reduces subcutaneous fat layers, particularly in areas of excessive accumulation, using low-temperature energy and negative pressure; Ulfit, which utilizes HIFU energy to improve skin elasticity and subcutaneous tissue in the abdomen and thighs; Refit, a medical device combining RF and negative pressure to elevate tissue temperature and blood flow, thereby alleviating pain in treated areas; AQUAPURE, equipped with four distinct handpieces for applications such as acne suction and various forms of pain relief, including muscle pain; and AQUAPURE II, a multi-functional device for comprehensive facial and body care. These products are marketed under the Classys, Cluederm, and SKEDERM brands. CLASSYS serves a broad client base, including clinics, hospitals, and beauty salons. The company was founded in 2007 and is headquartered in Seoul, South Korea.

SectorHealthcare
IndustryMedical - Devices
CountrySouth Korea
Trades inKRW

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

CLASSYS Inc. (214150.KQ)

214150.KQ · KOE · Healthcare
39,700.00-9.36%
Sign up to track this stock

No price history available.

KvantraRank51
P/E TTM19.2
P/E NTM18.1
Market cap3.16T
KvantraRank51 / 100
Value
37
Quality
75
Momentum
38
Financialsin KRW
20242025TTM2026E
Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

About

CLASSYS Inc. is a global supplier of sophisticated medical aesthetic devices. Its diverse product range features SCIZER, a non-invasive solution for subcutaneous fat reduction; ULTRAFORMER MPT, which employs focused ultrasound stimulation for skin tissue coagulation to achieve eyebrow lifts; and ULTRAFORMER III, a high-intensity focused ultrasound (HIFU) surgical device designed for tissue coagulation, aiding in eyelid lifting, skin tightening, and improving subcutaneous tissue elasticity across the face (cheeks), abdomen, and thighs, while also diminishing crow's feet, laugh lines, and neck wrinkles. Additional offerings include INTRASURE, a versatile multi-platform solution for aesthetics and healthcare; FORSHAPE, an RF treatment system engineered to boost metabolism, enhance blood circulation, and facilitate tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used for skin tissue coagulation as a general electrosurgical instrument. The company's portfolio further encompasses CLATUU Alpha, a medical device that progressively reduces subcutaneous fat layers, particularly in areas of excessive accumulation, using low-temperature energy and negative pressure; Ulfit, which utilizes HIFU energy to improve skin elasticity and subcutaneous tissue in the abdomen and thighs; Refit, a medical device combining RF and negative pressure to elevate tissue temperature and blood flow, thereby alleviating pain in treated areas; AQUAPURE, equipped with four distinct handpieces for applications such as acne suction and various forms of pain relief, including muscle pain; and AQUAPURE II, a multi-functional device for comprehensive facial and body care. These products are marketed under the Classys, Cluederm, and SKEDERM brands. CLASSYS serves a broad client base, including clinics, hospitals, and beauty salons. The company was founded in 2007 and is headquartered in Seoul, South Korea.

SectorHealthcare
IndustryMedical - Devices
CountrySouth Korea
Trades inKRW

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans